Meeting Mojo
Meeting Mojo, the event networking platform, is now live!
Once you have registered for the conference, you will receive your login details by email. Click here to log-in.
Please do not hesitate to contact us if you have any questions.
Why Attend
The CAR-T Congress gathers thought leaders from biotech, big pharma, academia and investment to address the challenges and opportunities of CAR-T therapies in both liquid and solid tumors. Discussing the potential of CARs in alternative cell types, mechanisms behind toxicity and tumor targeting, this event will provide an in depth view into this expansive area.
Exploring ground-breaking developments into CAR-T therapy, the event will provide the opportunity to collaborate to create a commercially viable, effective and safe therapy.
Key session topics include:
- Alternative cell constructs: TCRs, gamma delta T cells, CAR-NK & CAR-Tregs
- Commercialisation, regulation & implementation
- Safety, control & the underlying mechanisms of toxicity
- Scalability, automation & process development
- Target identification & neoantigen discovery
- Patient access & strategic considerations
- Investment & partnering workshops
Introducing dedicated partnering & networking sessions, with high level workshops to navigate the investment landscape & meet emerging companies. Join us for a rare opportunity to hear first-hand from those shaping the industry.
Take a look at our highlights video:
The Agenda
Simply fill in this form we'll send you a PDF version immediately. We need some information to know where to send the file and how to address our email to you.
Download Full Agenda
The Speakers
Ronald Dudek
Laurence Cooper
Joern-Peter Halle
Peter is leading the Translational Innovation Platform Immuno-Oncology with global responsibility for the research, discovery, and translational aspects of Merck KGaA’s IO portfolio. As the global head for External Innovation he oversees the search & evaluation of external opportunities in all therapeutic areas ranging from academic collaborations to clinical assets. He is also responsible for innovation initiatives of the healthcare business and a member of the investment committee of Merck Venture, Merck KGaA’s corporate VC. He started his carrier in Merck KGaA 12 years ago as a member of the corporate development. Prior to joining Merck KGaA, he co-founded a biotech company focusing on R&D in dermatology where he was responsible for IP, bioinformatics, and technology development and served as a Chief Business Officer.
Neil Sheppard
Robert Tighe
Matthew Hewitt
Scott Ohanesian
Mr. Scott Ohanesian has held executive roles over the past 14 years for Clinical Logistics Organizations and Contract Manufacturing Organizations (CMOs), managing global logistics for Phase I to Phase IV clinical trials.
He currently leads the QuickSTAT U.S. commercial operations team to build strategic relationships with pharmaceutical and biotech companies in order to provide comprehensive solutions for their global supply chain, ensuring product integrity and patient safety.
Prior to joining QuickSTAT, Scott managed the Asia Pacific commercial operations for Marken Limited, where he implemented the commercial strategy for his company in key markets, such as Australia, China, India, Japan, Singapore, South Korea, and Taiwan. Prior to that position, he was in a global strategic management role at a CMO, creating mutually beneficial partnership models.
He is trained and well versed in Good Manufacturing Practices, (GMP) and has helped create innovative logistics solutions for numerous new drug products--from formulation development through to commercialization, for pharmaceutical and biotech companies.
Scott is a graduate of Boston College with a Bachelor of Science in Finance and a Masters of International Law in Diplomacy from The Fletcher School at Tufts University, with affiliated course work at Harvard Law School and Harvard Business School.
Dr Bijal Shah
James Noble
Bob Valamehr, PhD MBA,
Andrew Allen
Dr David Sourdive, PhD
David Sourdive, Ph.D., is a co-founder of Cellectis and joined the Board of Directors in 2000. Dr. Sourdive holds the position of Executive Vice President, Technical Operations, with the mission to develop the Company’s industrial and technological basis as well as to deploy its operations in the pharmaceutical arena. Dr. Sourdive combines a strong scientific expertise with experience in managing industrial programs bringing innovative technologies to industrial fruition. He served as Executive Vice President, Corporate Development, from 2008 to 2016. In addition to his role at Cellectis, Dr. Sourdive has also served on the board of directors of the Mediterranean Institute for Life Sciences. David Sourdive graduated from École Polytechnique, received his Ph.D. in molecular virology at Institut Pasteur and completed a research fellowship in the Emory University Department of Microbiology and Immunology. His management training is from the HEC (Challenge +) and his decade-long experience in industrial program management was acquired at the French Department of Defense (DGA) prior to Cellectis’ inception.
Dr Yangbing Zhao
Dr. Yangbing Zhao is the Director of the T Cell Engineering Laboratory (TCEL), Center for Cellular Immunotherapies at the University of Pennsylvania. He received an MD and PhD in Immunology from the Third Medical University in Chongqing, China. From 1996 – 2000, he was a visiting scientist at The Weizmann Institute of Science in Rehovot, Israel, where he studied tolerance induction through genetically engineered T cells for allogeneic bone marrow transplantation. For the next two years he was a research associate at Duke University Medical Center, where he worked on RNA transfected dendritic cell vaccines against tumors. In 2003, he joined Dr. Steven Rosenberg’s group as a senior research fellow at the Surgery Branch of the National Cancer Institute, where his research work directly led to clinical trials of treating cancer patients with TCR or CAR engineered T cells against NY-ESO-1, Her2/Neu, CD19 or VEGFR. He joined the faculty of the Department of Pathology and Laboratory Medicine, University of Pennsylvania School of Medicine in 2009 as the Director of TCEL. His Laboratory’s research and development work has led to multiple clinical trials for the treatment of solid tumors with genetically engineered T cells against mesothelioma, pancreatic cancer, breast cancer and glioblastoma.
David Epstein
Gary C. Du Moulin, PhD
Lawrence Lamb
Michael Klichinsky
Stephane Boissel
Russell Cruz
Expertise Partner
Miltenyi Biotec
Website: www.miltenyibiotec.com
At Miltenyi Biotec, we are committed to enabling the delivery of new cell and gene therapy (CGT) treatment options to patients with unmet medical needs. We develop tailored cell processing protocols for our GMP-compliant cell processing platform, the CliniMACS Prodigy®, to enable fully closed and automated manufacturing of complex CGT products. In addition, we offer contract development and GMP manufacturing of CGT products as well as design, development, and production of tailored GMP lentiviral vectors
Thought Leadership Partners
QuickSTAT
Website: www.quickstat.aero
For 40 years, the Quick Group has been serving the life science and healthcare community worldwide, providing 24/7 priority logistics and transportation solutions for time and temperature-sensitive, mission-critical and life-saving needs.
Our specially trained life science team, with unmatched experience, provides innovative and best in class logistics solutions for cell and gene therapies that ensure regulatory compliance, product integrity and patient safety.
With a global network, Quick can expedite delivery to anywhere in the world -- even to the most remote locations. We provide consultation on regulatory compliance, classification, import/export documentation and Dangerous Goods.
Our temperature control experts provide consultation and procurement of the latest packaging solutions for all temperature ranges, GPS tracking and temperature-monitoring devices, ensuring product integrity and patient safety. Whether your shipments need to remain at Controlled Room Temperature, 2 to 8ºC, or cryo frozen, Quick will handle your shipments utilizing certified GDP and quality processes.
Quick’s market leading technology, QuickOnlineRX, provides comprehensive management of your supply chain logistics, with real-time tracking and status alerts, and is fully scalable to meet the requirements of newly commercialized products.
As the trusted leader in personalized medicine logistics and transportation, Quick provides customized solutions and protocols to ensure the safety and integrity of your CAR-T Therapies. We’ll help you plan, design and support your logistics operation, so you can focus on your core business - creating cutting-edge healthcare treatments.
Be The Match BioTherapies
Website: https://bethematchbiotherapies.com/
Be The Match BioTherapies partners with organizations pursuing life-saving cellular therapies in every stage of development – from discovery through commercialization. Built on the foundation established over the last 30 years by the National Marrow Donor Program®/Be The Match®, we have unparalleled experience managing cellular therapies.
Our cell therapy supply chain delivery for autologous or allogeneic therapies is enabled by high-touch, personalized case management and a robust, customizable technology platform, MatchSource. Our experience in cell sourcing and collection allows us to provide cells consented for research, clinical or commercial use. Researchers have access to clinical trial services through our research program, the CIBMTR. And, we have the infrastructure in place to collect, store and analyze patient samples post-cell or gene therapy treatment at the time points required by regulatory authorities.
Access our website: bethematchbiotherapies.com
Event Partners
BioSpherix
Website: www.BioSpherix.com
BioSpherix will be exhibiting the Xvivo System, the only cytocentric barrier isolator optimized for cells. Economical alternative to cleanrooms for cGMP compliant production of cells for clinical use. Stop by BioSpherix booth to learn more about the only total quality platform for cells!
Total quality recognizes that for best cell potency, cells need full-time optimization of all critical cell process parameters. Total quality recognizes that all typical negative side effects of machines on cells (particles, heat, vibration, etc.) must be neutralized and those machines must be protected from dust, aerosols, and corrosion. Total quality recognizes that each entire cell production line (all manual and automated steps) must be protected from microbial contamination. Total quality recognizes that all personnel must be fully protected from cells harboring virus, vectors, prion, and other pathogens. Total quality recognizes that scaling up and out must be efficient and cost efficient.
PRA Health Sciences
Website: www.prahs.com
PRA Health Sciences delivers innovative drug development solutions that improve patients’ lives. Our people are passionate about clinical research, working tirelessly to provide quality results for clients. We offer exceptional experience across all phases, therapeutic areas and a broad spectrum of solutions, ranging from full-service clinical development to our pioneering embedded model.
With 15,000+ employees covering 85+ countries, we bolster an impressive global presence with keen local insights. Our project teams harness their understanding of local regulations, standards of care and cultural customs to effectively align our approaches with each study’s unique goals.
At PRA, we love what do because we are making a difference in the lives of patients and their family members worldwide. Over the years, we have contributed to the development of numerous drugs now available to countless patients. From our scientific and medical experts to therapeutically aligned project managers and monitors, we provide the commitment and expertise needed for today’s complex studies.
TrakCel
Website: www.trakcel.com
A critical factor facing the industry is choosing technologies and partners that can deliver scale. The challenges inherent in translating early clinical trials to a reproducible and robust process suitable for scalable commercial production are very significant. Each personalized drug product ultimately depends on a sustainable and consistent supply chain with lots of moving parts. Configured to your exact demands, using an industry-standard framework, TrakCel’s comprehensive supply chain platform ensures every resource is managed, monitored, recorded and is ultimately performed exactly as required. From sample collection through logistics, manufacturing and final transplantation, with comprehensive chain of custody, chain of identity and traceability, TrakCel’s proven technology integrates and orchestrates every aspect of your autologous and allogeneic supply chains in a scalable, compliant and validated technology platform.
Dana Farber
Website: http://www.dana-farber.org
Since its founding in 1947, Dana-Farber Cancer Institute in Boston, Massachusetts has been committed to providing adults and children with cancer with the best treatment available today while developing tomorrow's cures through cutting-edge research. Read about our history, our breakthroughs, and the resources that help us support the health of our neighborhoods and communities.
CountStar
CountStar®
Smart Cell Analysis
Introducing Countstar® Cell Analysis Systems, a line of instruments with an innovative combination of advanced technologies. Countstar® brings together the functionality of digital microscopes, cytometers and automated cell counters into its intuitively designed systems. By combining bright-field and fluorescent imaging with classical dye-exclusion technologies, extensive data on cell morphology, viability, and concentration is generated in real time. Countstar® Systems go further by generating high-resolution images, the essential basis for sophisticated data analysis. With more than 1,000 analyzers installed worldwide, Countstar® analyzers are proven to be valuable tools in research, process development, and validated production environments.
The Countstar® brand was inspired by the endless possibilities a person experiences when counting stars in the night sky. With this approach, Countstar® explores the limits of technology. Countstar® was founded by ALIT Life Sciences, an emerging manufacturer of innovative equipment and consumables for the biological research community. Headquartered in the high-tech district of Shanghai, ALIT Life Sciences develops and produces the analytical equipment of the future.
Please meet us at the CAR-T Congress in Boston at the Hilton Boston/Dedham on March 20th through 22nd.
World Courier
Website: www.worldcourier.com
World Courier is a global specialty logistics company that designs world-class logistics and supply chain programs in complete alignment with our customers’ business goals. Pharmaceutical companies rely on us because they value the peace of mind that comes with our unsurpassed knowledge, global reach and flawless supply chain execution. Each trusted partnership we form with a customer is deeply rooted in our shared vision of improving global health. With 2,500+ associates in more than 140 offices across the globe, we offer solutions that instill confidence in the on-time, on-temperature delivery of critical products. When trust is absolutely essential, there’s only one choice: World Courier.
Media partners
BioInformant
Website: https://www.bioinformant.com
As the first and only market research firm to specialize in the stem cell industry, BioInformant research has been cited by the Wall Street Journal, Xconomy, and Vogue Magazine. Today, BioInformant.com is the world's largest publisher of cell therapy industry news, serving Fortune 500 leaders that include GE Healthcare, Pfizer, and Goldman Sachs.
Human Gene Therapy
Website: http://www.liebertpub.com/hgt
Human Gene Therapy is the premier, multidisciplinary journal covering all aspects of gene therapy. The Journal publishes in-depth coverage of DNA, RNA, and cell therapies by delivering the latest breakthroughs in research and technologies. Human Gene Therapy provides a central forum for scientific and clinical information, including ethical, legal, regulatory, social, and commercial issues, which enables the advancement and progress of therapeutic procedures leading to improved patient outcomes, and ultimately, to curing diseases.
The Journal is divided into three parts. Human Gene Therapy, the flagship, is published 12 times per year. HGT Methods, a bimonthly journal, focuses on the applications of gene therapy to product testing and development. HGT Clinical Development, a quarterly journal, serves as a venue for publishing data relevant to the regulatory review and commercial development of cell and gene therapy products.
Gene Therapy Net
Website: www.genetherapynet.com
Gene Therapy Net is the information resource for basic and clinical research in gene therapy, and the site serves as a network in the exchange of gene therapy information and breaking news items. Visitors can keep track of the latest scientific papers, conference announcements, gene therapy jobs, regulations and guidelines.
Onco' Zine
Website: www.oncozine.com
Onco’Zine, The International Oncology Network – is a Social Media based, journal relies heavily on in-person specialized coverage of scientific meetings and conferences. Correspondents throughout the United States, Canada and Europe supply first-hand reports and interviews with researchers, clinicians, and industry and government figures whose work and actions are changing the practice of oncology and hematology. As a Social Media based peer-to-peer/professional network Onco’Zine also welcomes contributions and discussions from healthcare professionals.
ADC Review
Website: www.adcreview.com
ADC Review / Journal of Antibody-drug Conjugates (ISSN 2327-0152) is an international publication combining professional social media with an online-only, hybrid open-access, peer reviewed journal.
The Journal is designed to serve the needs of a diverse community of individuals including academia, life sciences, pharma, (basic, translational and clinical) research, clinicians/physicians, along with regulatory affairs, government authorities and representatives from payers, and policy makers.
BioProcess International Magazine
Website: www.bioprocessintl.com
BioProcess International magazine covers the whole bioprocessing industry: biotherapeutic process and product development and biomanufacturing.
pharmaphorum
Website: https://pharmaphorum.com/
pharmaphorum is a content and communications company offering a unique hybrid of publisher and agency working in pharma and healthcare.
pharmaphorum.com is our own independent flagship publication. It serves over 3 million unique users annually and its news and information is widely recognised as a leading source of thought leadership and strategic content for pharmaceutical professionals all over the world.
Our innovative digital magazine Deep Dive provides cutting edge insight on pharma industry trends to an audience of 100K per issue.
Life Science Investing News
Website: https://investingnews.com/category/daily/life-science-investing/
The Investing News Network® (INN) publishes InvestingNews.com, a destination website for the investment community.
We provide independent, unbiased news and education for investors in over 40 targeted categories. Life Science Investing News is the part of InvestingNews.com that focuses on investment opportunities in the life science sector. We focus on medical devices, pharmaceuticals, biotech, longevity and genetics.
Our Mission
To become the world’s number one source of independent, unbiased news and education, and in doing so help investors realize their financial goals.
To be internationally respected for our integrity, our people and our commitment to excellence.
To create an environment where sophisticated investors can understand and connect directly with trusted organizations and businesses.
Please check InvestingNews.com for information on other investment areas we cover.
Please go to InvestingNewsNetwork.com for more information on our network and company.
UBM Medica
Website: http://www.cancernetwork.com/
As one of the largest healthcare media companies in the U.S., UBM Medica connects more than 3 million healthcare providers with unbiased, practical, clinical, and business information — helping improve the quality of care for patients around the world.
Through our longstanding relationship with HCPs, we create ideas that deliver results for clients, leveraging multimedia touchpoints designed to engage and inspire. Our portfolio of digital, print and event brands represent some of the most revered and recognized in the industry, reaching practitioners and decision makers in primary care, pediatrics, oncology, psychiatry, dermatology, aesthetics, eye care, neurology, obstetrics and gynecology, urology, managed care, pharmacy, and many more.
UBM Medica, through Cancer Network, is proud to be the official media partner with The CAR-T Congress.
Cell Therapy News
Website: www.celltherapynews.com
Connexon Creative’s mission is to accelerate science and facilitate science communication by providing tools that enhance the way scientific and medical professionals keep up with recent findings, science news and exciting advances in specific areas of immunology and cell biology research.
Accelerating Cancer Immunotherapy Research
Website: www.acir.org
ACIR.org’s mission is to accelerate Cancer Immunotherapy research by preparing a free-of-charge weekly synopsis of the key advances in this fast-moving and multifaceted field. Our scientists scour PubMed and curate the key publications we believe all researchers should be aware of.
We hope that by making it easier to stay up to date, our summary will enhance the productivity and creativity of many, bringing us closer to a cure.
Subscribe to our free newsletter at www.acir.org.
PARTNER WITH US
Based on your objectives, we can create bespoke packages designed specifically for you. Opportunities predominantly lie in 3 main categories: Thought Leadership, Branding, and Networking.
Interested in a media partnership?
We'd love to hear from you and how we can support one another to connect with the industry. Contact [email protected]
CAR-T Congress USA
Venue
Hilton Boston Dedham Hotel, 25 Allied Drive, Dedham, MA, 0206
Overlooking tranquil woods, and only 10 miles from downtown Boston, this year we've chosen the newly-renovated Hilton Boston/Dedham as our venue of choice.
Located off I-95, it is within close proximity to multiple train stations and there is a complimentary shuttle service allowing you to travel around easily.
Inside the hotel you’ll find modern and welcoming rooms and suites, great recreational amenities, vibrant local cuisine and stunning indoor/outdoor spaces. Book a room for only $109.00 + tax (based on single occupancy).
T: +1-781-329-7900
Remember to always quote “CART” when booking.
Conference Packages
Sending Your Team? Group Discounts Available!
Applicable for Primary Market, Service Provider and Industry Rates Only. Not available for Academic or ‘Start-Up’ rates
Book a Team of 3+ - Save an Additional 10% Off
Book a Team of 5+ - Save an Additional 15% Off
If you would like to register a team of 3 or more, please email [email protected] for your discount coupon code before registering. PLEASE NOTE: Discounts cannot be combined with Early Bird Pricing or any other discount or offer. If you have any questions about your registration, please call us on +44 (0)20 3696 2920
About Kisaco Research
Kisaco Research produces, designs and hosts B2B industry conferences, exhibitions and communities – focused on a specialized selection of topic areas.
Meet industry peers that will help build a career-changing network for life.
Learn from the mistakes of your peers as much as their successes—ambitious industry stalwarts who are happy to share not just what has made them successful so far but also their plans for future proofing their companies.
Note down the inspired insight that will form the foundation for future strategies and roadmaps, both at our events and through our online communities.
Invest both in your company growth and your own personal development by signing up to one of our events and get started.